- Social:
Harvard Medical School
Aaron Kesselheim is Associate Professor of Medicine at Harvard Medical School and Director of its Program on Regulation, Therapeutics and Law.
PROFILE
Aaron Kesselheim
Guest
FROM Aaron Kesselheim
To the Point
An old drug gets a ridiculously high price….again Are incentives for so-called "orphan drugs" being misused to jack up the price of one medication by 4000 percent? Photo by Chris Potter A rare form of muscular dystrophy has long been treated in the US by a steroid imported from overseas at a price of $1200 a year. Now the FDA has approved its manufacture and distribution in this country by the drug company Marathon. The new price is $89,000 a year — reduced to $54,000 after rebates and discounts. We get perspective from Carolyn Johnson, who covers the business of medicine for the Washington Post , and Dr. Aaron Kesselheim, a professor of medicine at Harvard, where he's also Director of the program on Regulation, Therapeutics and Law.
Press Play with Madeleine Brand
Doctors, Drug Companies and Transparency In an effort to get doctors to prescribe their drugs to patients, drug makers spend billions of dollars a year on meals, speaking and consulting fees, and other perks for physicians. Today, a new government database goes online that will list the money pharmaceutical companies spend on doctors.
Recommended
Left, Right & Center
The week that wouldn't quit Will next week get even weirder? (Special one-hour episode)
To the Point
Janesville and the American Dream Janesville, Wisconsin is the hometown of Republican House Speaker Paul Ryan. But he couldn’t prevent the closing of the General Motors factory after 100 years. On this Memorial Day rebroadcast of To the Point, we hear what’s happened to what once was a model of American middle-class unity.
To the Point
Replacing Obamacare: Now you see it… now you don’t As the Senate deliberates replacing Obmacare, health coverage for millions of people is at stake. There've been no public hearings, and a draft measure won't be made public. Is the House version so unpopular that that Senate is hiding a version that looks much the same?